Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (445)	9/1/2003 5:13:21 PM
From: Icebrg	Read Replies (1) \| Respond to of 631

Fresh from the pipeline Adalimumab Bornadata Bain1 & Melanie Brazil2 1 Bornadata Bain is at Decision Resources Inc., 260 Charles Street, Waltham, Massachusetts 02453, USA. 2 Melanie Brazil is at Nature Reviews Drug Discovery. Adalimumab (Humira; Abbott), an antibody that binds specifically to the inflammatory cytokine TNF-, was approved by the US FDA for the treatment of moderate to severe rheumatoid arthritis in December 2002. Does the launch of adalimumab, which is the first fully human antibody to be approved as a therapeutic, sound the death knoll for chimeric and humanized antibodies? nature.com